Clinical trials in Bordeaux – page 15

1 164 clinical trials in Bordeaux, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Bordeaux at a glance

1 164

clinical trials

Research sites2

Quick filters

1 164 trials in Bordeaux

Open in trial search

Sarcoma+4

Recruiting

Study of zanidatamab in adult patients with HER2-positive solid tumors (endometrial, colorectal, head & neck, sarcoma) or HER2-mutant non-small cell lung cancer

InvestigationalNo placebo

Study of zanidatamab in adult patients with HER2-positive solid tumors (endometrial, colorectal, head & neck, sarcoma) or HER2-mutant non-small cell lung cancer

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Zanidatamab
Sponsor:Unicancer

Contact Research Centre

Neoplasm

Recruiting

Study on the Safety and Effects of EIK1004 for Patients with Advanced Solid Tumors

InvestigationalNo placebo

Study on the Safety and Effects of EIK1004 for Patients with Advanced Solid Tumors

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Sponsor:Eikon Therapeutics Inc.

Contact Research Centre

Neuroblastoma

Recruiting

Study of Temozolomide, Topotecan, Bevacizumab, Irinotecan and Dinutuximab Beta in Patients with High-Risk Relapsed Neuroblastoma

Registered drugNo placebo

Study of Temozolomide, Topotecan, Bevacizumab, Irinotecan and Dinutuximab Beta in Patients with High-Risk Relapsed Neuroblastoma

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years
Substances:Bevacizumab
Sponsor:The University Of Birmingham

Contact Research Centre

Malignant melanoma

Recruiting

Vusolimogene Oderparepvec with Nivolumab for Advanced Melanoma Patients Whose Cancer Progressed After Previous Immunotherapy Treatments

Registered drugNo placebo

Vusolimogene Oderparepvec with Nivolumab for Advanced Melanoma Patients Whose Cancer Progressed After Previous Immunotherapy Treatments

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Dacarbazine Citrate
Sponsor:Replimune Group Inc.

Contact Research Centre

Endometrial cancer

Recruiting

Study of Trastuzumab Deruxtecan, Rilvegostomig, and Pembrolizumab for Advanced or Recurrent Endometrial Cancer in HER2-Positive Patients

Registered drugNo placebo

Study of Trastuzumab Deruxtecan, Rilvegostomig, and Pembrolizumab for Advanced or Recurrent Endometrial Cancer in HER2-Positive Patients

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:AstraZeneca AB

Contact Research Centre

Psoriatic arthropathy

Recruiting

Study on Lutikizumab and Risankizumab for Adults with Active Psoriatic Arthritis

InvestigationalNo placebo

Study on Lutikizumab and Risankizumab for Adults with Active Psoriatic Arthritis

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Lutikizumab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Endometrial cancer

Recruiting

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Advanced or Recurrent Endometrial Cancer

Registered drugNo placebo

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Advanced or Recurrent Endometrial Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Renal transplant

Recruiting

Study of Belatacept versus Tacrolimus in Kidney Transplant Recipients with Subclinical Antibody Mediated Rejection

Registered drugNo placebo

Study of Belatacept versus Tacrolimus in Kidney Transplant Recipients with Subclinical Antibody Mediated Rejection

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Belatacept
Sponsor:Centre Hospitalier Universitaire Rouen

Contact Research Centre

Study of Rilvegostomig or Pembrolizumab for First-line Treatment in Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer

Recruiting

Registered drugNo placebo

Study of Rilvegostomig or Pembrolizumab for First-line Treatment in Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Infliximab
Sponsor:AstraZeneca AB

Contact Research Centre

Study on the Safety and Immune Response of the MVA-BN Vaccine Booster for Monkeypox Prevention in Previously Vaccinated Patients

Recruiting

Registered drugNo placebo

Study on the Safety and Immune Response of the MVA-BN Vaccine Booster for Monkeypox Prevention in Previously Vaccinated Patients

Registered drugNo placebo

France

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:Modified Vaccinia Ankara – Bavarian Nordic Live Virus
Sponsor:The Public Health Agency Of Sweden

Contact Research Centre

Non-small cell lung cancer+2

Recruiting

Study Comparing Nivolumab and Relatlimab with Chemotherapy to Pembrolizumab with Chemotherapy for Advanced Non-Small Cell Lung Cancer Patients

Registered drugNo placebo

Study Comparing Nivolumab and Relatlimab with Chemotherapy to Pembrolizumab with Chemotherapy for Advanced Non-Small Cell Lung Cancer Patients

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study Comparing Tepotinib to Standard Treatment for Patients with Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo

Study Comparing Tepotinib to Standard Treatment for Patients with Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Bordeaux

What the registry says about research in the country

01 Autoimmune & Inflammatory Conditions

Innovative research focusing on psoriatic arthritis and hidradenitis suppurativa, evaluating new therapeutic combinations and treatment strategies. Studies explore the effectiveness of targeted therapies and novel approaches like fecal microbiota transplantation.

Psoriatic Arthritis Treatment
Inflammatory Skin Conditions
Myasthenia Gravis Management

Clinical trials aim to improve patient outcomes through combination therapies and innovative treatment approaches.

02 Oncology Research

Comprehensive studies investigating treatments for various cancers, including head and neck squamous cell carcinoma, endometrial cancer, and bladder cancer. Research focuses on immunotherapy combinations and targeted treatments.

Advanced Cancer Therapies
Immunotherapy Approaches
Targeted Treatment Strategies

Trials evaluate novel drug combinations and therapeutic approaches for better cancer treatment outcomes.

03 Transplant Medicine

Ground-breaking research in kidney transplantation, focusing on preventing rejection and improving long-term outcomes. Studies evaluate new immunosuppressive strategies and antibody-mediated rejection treatments.

Transplant Rejection Prevention
Immunosuppressive Therapies
Long-term Outcome Studies

Research aims to enhance transplant success rates and patient quality of life.

04 Neurological & Mental Health

Studies examining multiple sclerosis, narcolepsy, and major depressive disorder. Research investigates neuroinflammation patterns and innovative treatment approaches.

Brain Inflammation Studies
Sleep Disorders
Depression Treatment

Trials focus on understanding disease mechanisms and developing targeted therapies.

Back to France All countries